GWS
EGRX

Glassman Wealth Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Glassman Wealth Services’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-59
Closed -$930 – 2096
2023
Q3 		$930 Buy
59
+52
+743% +$934 ﹤0.01% 1573
2023
Q2 		$136 Sell
7
-3
-30% -$71 ﹤0.01% 1869
2023
Q1 		$284 Buy
+10
New +$297 ﹤0.01% 1723

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Glassman Wealth Services's EGRX Position: Q4 2023 in Review

Glassman Wealth Services sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 59 shares — an estimated $930 sold.

Glassman Wealth Services first reported a position in EGRX in Q1 2023 and held it in 3 quarters. The position peaked at $930 in Q3 2023. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

  • Glassman Wealth Services reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Glassman Wealth Services sold 59 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $930.
  • Glassman Wealth Services first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2023 and held it in 3 quarters.
  • Glassman Wealth Services's Eagle Pharmaceuticals, Inc. position peaked at $930 in Q3 2023.
  • 104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Glassman Wealth Services's 13F filing for Q4 2023, filed 12 Feb 2024.